Research To Practice | Oncology Videos

Featuring perspectives from Ms Ilene Galinsky, Dr Andrew T Kuykendall, Dr Sara M Tinsley-Vance and Dr Abdulraheem Yacoub, including the following topics: Introduction (0:00) The Biology of Myelofibrosis (MF) (14:00) Role of Available and Investigational JAK inhibitors for the Management of MF (45:49) Promising Agents and Strategies for Patients with MF (1:23:17) NCPD information and select publications

Featuring perspectives from Ms Courtney Arn, Dr Floor J Backes, Dr Kathleen N Moore and Ms Jaclyn Shaver, including the following topics: Introduction: The Incidence, Pathogenesis and Prognosis of Ovarian Cancer (0:00) Genetic Testing for Newly Diagnosed Advanced Ovarian Cancer (11:01) The Role of PARP Inhibitor Maintenance for Newly Diagnosed Advanced Ovarian Cancer (19:02) Side Effects Associated with PARP Inhibitors (29:58) Dosing, Adherence and Other Issues with PARP Inhibitors for Ovarian Cancer (48:29) The Potential Role of PARP Inhibitors in Combination with Anti-PD-1/PD-L1 Antibodies for Advanced Ovarian Cancer Management (54:11) PARP Inhibitors for Relapsed/Refractory Ovarian Cancer (1:00:36) The Current Role of Mirvetuximab Soravtansine for Ovarian Cancer Treatment (1:07:14) Toxicities with Mirvetuximab Soravtansine (1:11:53) The Incidence and Management of HER2-Positive Ovarian Cancer (1:18:18) NCPD information and select publications

Featuring perspectives from Ms Meetal Dharia, Dr Robert L Ferris, Dr Robert Haddad and Ms Lynsey P Teulings, including the following topics: Introduction (0:00) The Biology of Head and Neck Cancer (15:41) The Multidisciplinary Treatment of Head and Neck Cancer (18:14) Ongoing Screening and Prevention After Potentially Curative Therapy for Head and Neck Cancer (33:03) Radiation Therapy and Chemotherapy Side Effects (41:02) The Potential Short- and Long-Term Effects of Surgery for Head and Neck Cancer (49:50) Emerging Treatment Strategies Aimed at Improving Outcomes Associated with Localized or Locally Advanced Head and Neck Cancer (56:46) Tolerability Considerations with Xevinapant (1:06:13) The Established Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Advanced Head and Neck Cancer (1:17:35) Newly Approved Immunotherapeutic Strategies for Nasopharyngeal Carcinoma (1:19:27) The Tolerability of Immune Checkpoint Inhibitors (1:24:09) NCPD information and select publications

Featuring perspectives from Dr Rahul Aggarwal, Dr Adam S Kibel, Dr Laurence Klotz and Dr Sandy Srinivas, moderated by Dr Elisabeth I Heath, including the following topics: Introduction (0:00) Recent Data Defining the Optimal Use of Hormonal Therapy for Nonmetastatic Prostate Cancer — Dr Kibel (2:39) Side Effects and Other Practical Considerations with Hormonal Therapy for Nonmetastatic Prostate Cancer — Dr Klotz (27:04) Current and Future Approaches to Hormonal Therapy for Metastatic Prostate Cancer — Dr Aggarwal (51:07) New Considerations with the Use of PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Srinivas (1:13:53) Other Novel Therapies for Patients with Metastatic Prostate Cancer — Dr Heath (1:38:52) CME information and select publications

Featuring perspectives from Dr Andrew D Zelenetz, including the following topics: Follicular Lymphoma (0:00) Mantle Cell Lymphoma (30:29) Diffuse Large B-Cell Lymphoma (55:01) Hodgkin Lymphoma (1:12:25) CME information and select publications

Featuring a slide presentation and related discussion from Dr Elias Jabbour, including the following topics: Clinical management of Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL); factors in the selection of initial induction treatment (0:00) Primary and secondary endpoint outcomes from the Phase III PhALLCON trial comparing ponatinib to imatinib, each with reduced-intensity chemotherapy, as front-line treatment for Ph-positive ALL (5:22) Efficacy and tolerability of ponatinib in combination with blinatumomab for patients with newly diagnosed Ph-positive ALL (17:04) Ongoing research with novel agents and strategies for Ph-positive ALL (24:47) CME information and select publications

Featuring an interview with Dr Elias Jabbour, including the following topics: Evolution of research and therapeutic options for acute lymphoblastic leukemia (ALL) (0:00) Clinical and biological characteristics of ALL and implications for prognosis and disease management (6:36) Case: A 48-year-old woman with newly diagnosed Philadelphia chromosome-positive (Ph-positive) ALL attains complete remission with ponatinib/blinatumomab (14:03) Tolerability and improved quality of life with the chemotherapy-free combination of ponatinib and blinatumomab (24:17) Case: A 38-year-old man with newly diagnosed Ph-positive ALL experiences a complete molecular response with induction hyper-CVAD and ponatinib (27:10) CME information and select publications

Featuring a slide presentation and related discussion from Dr Joshua Richter, including the following topics: Similarities and differences between the cellular targets and mechanisms of action of BCMA- and non-BCMA-directed bispecific antibodies for multiple myeloma (MM) (0:00) Antitumor activity observed with teclistamab and elranatamab for relapsed/refractory MM (3:46) Published findings with investigational anti-BCMA bispecific antibodies such as linvoseltamab and alnuctamab for pretreated MM (12:40) Efficacy and safety of approved and investigational non-BCMA-targeted bispecific antibodies in patients with heavily pretreated MM (16:26) Early data with bispecific antibodies in combination with other systemic therapies for MM (22:55) Spectrum, incidence, severity and timing of cytokine release syndrome, neurotoxicity and other adverse events with BCMA- and non-BCMA-targeted bispecific antibodies (26:39) CME information and select publications

Featuring an interview with Dr Joshua Richter, including the following topics: Management of cytokine release syndrome after bispecific antibody therapy; importance of clinical trials in the multiple myeloma (MM) treatment paradigm (0:00) Similarities and differences between and efficacy and tolerability of BCMA- and non-BCMA-directed bispecific antibodies in the treatment of MM (7:18) Case: A woman in her mid 60s with penta-refractory MM who achieves complete remission with linvoseltamab on a clinical trial (12:53) Case: A woman in her early 60s with multiregimen-refractory MM who experiences pain and tumor flare during step-up dosing of teclistamab (22:40) Case: A man in his late 60s with relapsed/refractory MM who experiences disease relapse 18 months after chimeric antigen receptor T-cell therapy begins treatment with talquetamab (28:34) Racial and ethnic disparities in the treatment of MM (32:09) CME information and select publications

Featuring perspectives from Ms Blanca Ledezma, Dr Stacey Stein, Ms Amanda K Wagner and Dr Mark Yarchoan, including the following topics: Introduction (0:00) Adjuvant Therapy for Early-Stage Hepatocellular Carcinoma (HCC) (9:40) Role of Immunotherapy in Intermediate-Stage HCC (17:02) First-Line Therapy for Advanced HCC (19:56) Immunotherapy in the Management of Advanced Biliary Tract Cancers (BTCs) (44:29) Biomarker Testing Recommendations and the Use of FGFR Inhibitors for Advanced Cholangiocarcinoma (58:02) Potential Role of HER2-Targeted Therapy for BTCs (1:17:16) CME information and select publications

Featuring perspectives from Dr Adam M Brufsky, including the following topics: Review of Local Therapy (0:00) Treatment Advances for HER2 Positive Early-Stage Breast Cancer (18:35) Case: A woman in her early 60s with ER-positive, HER2-positive (IHC 3+) with infiltrating ductal carcinoma who received T-DM1 with an aromatase inhibitor (19:37) Case: A woman in her early 50s with ER-positive, HER2-positive (IHC 3+) who received TCHP followed by a mastectomy (56:26) Beyond the Guidelines Survey and HERRISK (1:02:23) Trials in Progress (1:14:44) CME information and select publications

Featuring perspectives from Ms Jennifer Filipi, Ms Kathryn Lyle, Dr David O'Malley and Dr Shannon N Westin, including the following topics: Introduction (0:00) Incidence and Biology of Endometrial Cancer (EC) (9:30) Use of Immune Checkpoint Inhibitors as Monotherapy for EC (23:24) First-Line Therapy for Primary Advanced or Recurrent EC (28:28) Lenvatinib/Pembrolizumab in the Management of Metastatic EC (1:05:08) Potential Role of Selinexor in the Management of EC (1:13:20) Incidence and Management of HER2-Positive EC (1:22:51) NCPD information and select publications

Featuring perspectives from Dr Andrew J Armstrong and Ms Brenda Martone, including the following topics: Introduction: Overview of Prostate Cancer; Hormonal Therapy (0:00) Radiopharmaceuticals for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) (24:11) Biomarker Testing for mCRPC; PARP Inhibitors for mCRPC (49:33) NCPD information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia | Faculty Presentation 2: Available and Emerging Nontargeted Therapies for AML — Naval Daver, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia | Faculty Presentation 1: Current and Emerging Role of Biomarker-Directed Therapeutic Approaches for Patients with Acute Myeloid Leukemia (AML) — Courtney D DiNardo, MD, MSCE CME information and select publications

Featuring perspectives from Dr Naval Daver and Dr Courtney D DiNardo, including the following topics: Introduction (0:00) Available and Emerging Nontargeted Therapies for Acute Myeloid Leukemia (AML) —Dr Daver (6:47) Current and Emerging Role of Biomarker-Directed Therapeutic Approaches for Patients with AML —Dr DiNardo (32:58) CME information and select publications

Featuring perspectives from Ms Marianne J Davies, Dr Alexander I Spira, Ms Jillian Thompson and Dr Helena Yu, including the following topics: Introduction (0:00) The Importance of EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) (7:02) The Role of Osimertinib in Managing Localized and Locally Advanced NSCLC with an EGFR Mutation (11:58) Established First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (32:38) Newly Approved and Promising Investigational Approaches to First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (37:45) Common Toxicities Associated with Amivantamab (45:07) The Current and Future Management of Progressive NSCLC with an EGFR Mutation (55:06) Tolerability and Other Practical Considerations with HER3-DXd (1:01:06) Treatment for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations (1:18:26) NCPD information and select publications

Featuring perspectives from Dr Julia Foldi, Dr Laura Huppert, Dr Rita Nanda, Dr Saba Shaikh and Dr Sara M Tolaney, including the following topics: Introduction: Overview of metastatic triple-negative breast cancer (mTNBC) Current and emerging strategies for patients with mTNBC (0:00) First-line treatment of mTNBC — Chemotherapy with or without immunotherapy Case: A woman in her early 60s with a history of well-controlled HIV is diagnosed with mTNBC — Dr Shaikh (6:10) Case: A woman in her mid 40s with de novo mTNBC — Dr Huppert (20:41) Case: A woman in her late 50s with mTNBC receives up-front pembrolizumab/chemotherapy — Dr Foldi (42:15) Antibody-drug conjugates (ADCs) in the management of mTNBC ADCs in the management of mTNBC; sequencing of these agents and ongoing investigations (51:45) Case: A woman in her early 50s with mTNBC receives first-line chemotherapy/immune checkpoint inhibitor followed by sacituzumab govitecan — Dr Shaikh (1:05:32) Case: A woman in her late 30s with mTNBC receives sacituzumab govitecan — Dr Huppert (1:14:21) Case: A woman in her early 40s with mTNBC (IHC 1+) with sacituzumab govitecan-intolerant disease experiences an excellent response to trastuzumab deruxtecan (T-DXd) — Dr Foldi (1:27:30) Case: A woman in her mid 50s with HER2-low metastatic breast cancer receives T-DXd — Dr Shaikh (1:42:00) PARP inhibition for the treatment of mTNBC Efficacy and tolerability of olaparib in patients with a germline BRCA mutation and HER2-negative breast cancer (1:49:49) Case: A woman in her mid 30s with mTNBC receives olaparib — Dr Foldi (1:54:28) Case: A woman in her mid 60s with mTNBC and a BRCA mutation receives olaparib — Dr Huppert (1:59:11) Case: A woman in her mid 40s with a BRCA1 germline mutation and mTNBC receives olaparib — Dr Shaikh (2:03:45) CME information and select publications

Featuring perspectives from Dr Matthew D Galsky, including the following topics: HER2 alterations in urothelial cancer and current targeting approaches (0:00) Key findings supporting the use of trastuzumab deruxtecan for patients with HER2-overexpressing cancers as part of the Phase II DESTINY-PanTumor02 study (9:39) Targeting of HER2 using disitamab vedotin both as a monotherapy and in combination with other treatments (14:31) Case: A man in his late 70s with a history of non-muscle-invasive bladder cancer who develops HER2-positive lung metastases (28:57) Case: A man in his late 60s who receives disitamab vedotin for HER2 IHC 2+ metastatic urothelial cancer (36:25) Enfortumab vedotin and pembrolizumab as first-line or neoadjuvant therapy for targeting HER2-expressing cancers (39:34) Future direction of HER2-targeting therapies for urothelial bladder cancer (1:02:48) CME information and select publications

Featuring a slide presentation and related discussion from Dr Sunnie Kim, including the following topics: Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer — Dr Kim (0:00) Case: A man in his mid 50s with poorly differentiated mismatch repair-deficient advanced gastric cancer receives first-line nivolumab/ipilimumab (49:22) Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma who experienced disease progression on FOLFOX/trastuzumab receives trastuzumab deruxtecan (54:48) Case: A man in his mid 60s with Stage IV, PD-L1-positive GEJ adenocarcinoma (58:11) Case: A man in his early 40s with metastatic CLDN18.2-positive gastric/GEJ adenocarcinoma receives zolbetuximab (1:01:10) CME information and select publications

Featuring perspectives from Prof Eric Van Cutsem, including the following topics: Immune Checkpoint Inhibitors in Localized Gastroesophageal (GE) Cancers Introduction (0:00) Case: A man in his mid 50s with localized, poorly differentiated signet ring, mismatch repair-deficient advanced gastric adenocarcinoma — Sunnie Kim, MD (3:39) HER2-Positive GE Cancers Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma and disease progression on FOLFOX/trastuzumab (PD-L1 CPS 0) — Dr Kim (19:22) First-Line Treatment of Metastatic Gastric and GEJ Adenocarcinoma Case: A man in his early 40s who presents with metastatic GEJ adenocarcinoma (CLDN18.2-positive, PD-L1 CPS 2) in visceral crisis from lung metastases — Dr Kim (38:53) Case: A man in his mid 60s with metastatic GEJ adenocarcinoma (PD-L1 CPS 20) — Dr Kim (50:50) CME information and select publications

Featuring perspectives from Dr Ruben A Mesa, including the following topics: Introduction: Journal Club with Dr Mesa (0:00) Case: A woman in her mid 80s with an interesting and unusual presentation of primary myelofibrosis — Bhavana (Tina) Bhatnagar, DO (25:33) Case: A man in his early 70s, asymptomatic, with lower-risk primary MF (JAK2 V617F mutation) — Susannah Friemel, MD (29:42) Case: A woman in her early 80s with pancytopenia and palpable spleen who is diagnosed with primary MF — Jeanne Palmer, MD (35:08) Case: A man in his early 70s with multiple comorbidities and MF (CALR mutation) who receives ruxolitinib 10 mg BID — Ranju Gupta, MD (42:40) ASH 2023 Review (46:13) Faculty Survey (55:41) CME information and select publications

Featuring perspectives from Prof Nicoletta Colombo, Dr Matthew A Powell and Dr Brian M Slomovitz, moderated by Dr Shannon N Westin, including the following topics: Introduction (0:00) Current Approaches to First-Line Therapy for Advanced Endometrial Cancer (EC) — Prof Colombo (1:57) Novel Investigational Strategies for Newly Diagnosed EC — Dr Westin (25:35) Current Options for Relapsed/Refractory EC — Dr Slomovitz (45:57) Role of HER2-Targeted Therapy in the Management of Advanced EC — Dr Powell (1:05:54) CME information and select publications

Featuring perspectives from Dr Carlos M de Castro III, Prof Alexander Röth and Dr Ilene Ceil Weitz, including the following topics: Introduction: A Paroxysmal Nocturnal Hemoglobinuria (PNH) Audio Primer for General Medical Oncologists (0:00) Biology and Current Clinical Management of PNH (36:35) Future Directions in PNH Management (55:34) Tolerability and Other Practical Considerations with Available and Emerging Treatments for PNH (1:14:26) CME information and select publications

Featuring an interview with Dr Emmanuel S Antonarakis, including the following topics: Perspectives on advances in the management of prostate cancer over the last decade (0:00) Nonmetastatic high-risk prostate cancer and androgen deprivation therapy (ADT) intensification with abiraterone: Insights from the STAMPEDE trial (7:39) EMBARK: A Phase III trial of enzalutamide or placebo with leuprolide acetate and enzalutamide monotherapy for high-risk biochemically recurrent prostate cancer (15:25) Quality of life and preservation of sexual function with enzalutamide monotherapy compared to ADT alone or enzalutamide with ADT (20:20) Management of locally advanced prostate cancer with and without biochemical recurrence (23:58) PRESTO trial of ADT intensification with apalutamide with or without abiraterone for high-risk biochemically relapsed prostate cancer (30:35) CDK4/6 inhibitors, proteolysis-targeting chimeras and other novel therapeutic approaches for targeting androgen receptor signaling in prostate cancer (31:41) Choice of endocrine partner with ADT and incorporation of docetaxel in the treatment of metastatic hormone-sensitive prostate cancer (35:38) Other potential novel therapeutic strategies for prostate cancer (42:28) Integration of genomic testing for patients with prostate cancer; PARP inhibitor combinations for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (43:57) Incorporation of radiopharmaceuticals (ie, lutetium Lu 177 vipivotide tetraxetan, radium-223) into the management of prostate cancer (52:49) Perspectives on the results of the Phase III CONTACT-02 trial evaluating cabozantinib in combination with atezolizumab for mCRPC (57:44) CME information and select publications

Featuring perspectives from Dr Naveen Pemmaraju, including the following topics: Recent developments in management approaches for myelofibrosis prior to ASH 2023 (0:00) Updated data with navitoclax in combination with ruxolitinib for patients with myelofibrosis (12:35) Key findings with pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve myelofibrosis in the Phase III MANIFEST-2 study (22:21) Long-term follow-up from the Phase I/III XPORT-MF-034 trial of selinexor with ruxolitinib for JAK inhibitor-naïve myelofibrosis (29:10) Effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis treated with ruxolitinib in the expanded-access JUMP study (34:33) Results from the Phase III FREEDOM-2 study of fedratinib for patients with myelofibrosis after prior ruxolitinib (40:38) Landmark survival analysis of the Phase III PERSIST-2 trial evaluating pacritinib versus best available therapy in patients with myelofibrosis and thrombocytopenia (43:08) Retrospective analysis of the PAC203 and PERSIST-2 studies of pacritinib for cytopenic myelofibrosis (47:56) Longitudinal assessment of transfusion intensity in patients who received momelotinib for myelofibrosis in the Phase III SIMPLIFY-1 and MOMENTUM trials (52:48) Two-year follow-up from the Phase II REVIVE study of rusfertide in phlebotomy-dependent patients with polycythemia vera (55:18) Available Phase I/II data with the novel agent zilurgisertib with or without ruxolitinib in patients with anemia due to myelofibrosis (58:56) CME information and select publications

Featuring perspectives from Dr Andrew H Ko and Dr Eileen M O'Reilly, including the following topics. Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (PAD) — Dr Ko (0:00) Biomarker-Based Strategies for Metastatic PAD; Novel Investigational Approaches — Dr O'Reilly (31:46) CME information and select publications

Featuring perspectives from Dr Kristen K Ciombor and Dr John Strickler, including the following topics. Select Biomarker-Directed Approaches for Colorectal Cancer (CRC) — Dr Ciombor (0:00) HER2-Targeted Approaches for Metastatic CRC (mCRC); Other Available and Emerging Therapeutic Strategies — Dr Strickler (25:17) CME information and select publications

Featuring perspectives from Dr Ghassan Abou-Alfa and Dr Richard S Finn, including the following topics. Introduction (0:00) Hepatocellular Carcinoma (HCC) — Dr Abou-Alfa (8:30) Biliary Tract Cancers (BTCs) — Dr Finn (33:16) CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, including the following topics. Current and Potential Role of Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancers — Dr Klempner (0:00) Other Available and Emerging Therapeutic Approaches — Dr Janjigian (31:42) CME information and select publications

Featuring perspectives from Dr Natalie S Callander and Dr Paul G Richardson, including the following topics. Introduction (0:00) Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates in Multiple Myeloma (MM) — Dr Callander (8:25) Integration of Other Novel Therapies into the Management of Newly Diagnosed and Relapsed/Refractory MM — Dr Richardson (31:52) CME information and select publications

Featuring perspectives from Dr Edward B Garon and Dr Corey J Langer, including the following topics. Role of Immune Checkpoint Inhibitors in Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) — Dr Langer (0:00) Immune Checkpoint Inhibitors and Other Emerging Therapeutic Approaches for Metastatic NSCLC without a Targetable Tumor Mutation — Dr Garon (30:08) CME information and select publications

Featuring perspectives from Dr Ibiayi Dagogo-Jack and Dr Henela Yu, including the following topics. Management of Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Dr Yu (0:00) Care of Individuals with Other Targetable Genomic Abnormalities — Dr Dagogo-Jack (31:01) CME information and select publications

Featuring perspectives from Dr Emmanuel S Antonarakis and Dr Rana R McKay, including the following topics. Role of Hormonal Therapy in Prostate Cancer (PC) Management — Dr McKay (0:00) Evidence-Based Use of Other Therapeutic Approaches — Dr Antonarakis (35:15) CME information and select publications

Featuring perspectives from Dr Matthew D Galsky and Dr Jonathan E Rosenberg, including the following topics. Introduction (0:00) Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Galsky (5:45) Metastatic UBC — Dr Rosenberg (31:51) CME information and select publications

Featuring perspectives from Dr Eric Jonasch and DR Brian Rini, including the following topics. Introduction (0:00) Current Management of Metastatic Clear Cell Renal Cell Carcinoma (RCC) — Dr Rini (5:11) Treatment Approaches for Nonmetastatic RCC; Optimal Care of Patients with Non-Clear Cell RCC — Dr Jonasch (38:52) CME information and select publications

Featuring perspectives from Dr Erika Hamilton, Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics. HER2-Positive Metastatic Breast Cancer — Dr Hamilton (0:00) Metastatic Triple-Negative Breast Cancer — Dr Rugo (29:06) SABCS® 2023 Review — Dr Kaklamani (45:20) CME information and select publications

Featuring perspectives from Dr Virginia Kaklamani, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics. Introduction (0:00) Localized HER2-Positive and Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:52) SABCS® 2023 Review — Dr Kaklamani (31:48) Localized ER-Positive Breast Cancer — Dr Kalinsky (38:10) CME information and select publications

Featuring perspectives from Dr Bradley J Monk and Dr David M O'Malley, including the following topics. Introduction (0:00) Ovarian Cancer; Role of HER2-Directed Therapy in Gynecologic Cancers — Dr O'Malley (4:36) Endometrial Cancer and Cervical Cancer — Dr Monk (27:59) CME information and select publications

Featuring perspectives from Dr Ann S LaCasce, Dr Matthew Lunning, Dr Kami Maddocks and Dr Andrew D Zelenetz, including the following topics. Introduction (0:00) Follicular Lymphoma (FL) — Dr Zelenetz (2:29) Mantle Cell Lymphoma (MCL) — Dr Lunning (32:04) Hodgkin Lymphoma (HL) — Dr LaCasce (1:00:36) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Maddocks (1:18:53) CME information and select publications

Featuring perspectives from Dr Erika Hamilton, Dr Kevin Kalinsky, Dr Joyce O'Shaughnessy and Dr Hope S Rugo, including the following topics. Introduction (0:00) Optimal Integration of CDK4/6 Inhibitors into the Management of ER-Positive Metastatic Breast Cancer (mBC) — Dr O'Shaughnessy (5:46) Role of Oral Selective Estrogen Receptor Degraders (SERDs) in the Treatment of ER-Positive mBC — Dr Hamilton (43:06) Novel Strategies Targeting the PI3K/AKT/mTOR Signaling Pathway in ER-Positive mBC — Dr Kalinsky (57:22) Current and Future Role of Antibody-Drug Conjugates (ADCs) in the Management of ER-Positive mBC — Dr Rugo (1:17:49) Breast Cancer in the Real World (1:40:29) CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr Mansoor Raza Mirza and Dr David M O'Malley, moderated by Dr Kathleen N Moore, including the following topics: Introduction (0:00) Current Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Liu (2:06) Potential Role of Immunotherapeutic Strategies for Advanced OC — Dr O'Malley (25:12) Incorporation of Novel Therapies into the Management of Relapsed/Refractory OC — Dr Moore (48:23) Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced OC — Dr Mirza (1:06:59) CME information and select publications

Featuring a slide presentation and related discussion from Dr Kanwal Raghav, including the following topics: Prevalence of HER2 alterations among patients with advanced gastrointestinal tumors beyond gastroesophageal cancer (0:00) Dual HER2 inhibition in the treatment of HER2-amplified colorectal cancer (CRC) (4:56) Efficacy and tolerability of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing metastatic CRC (8:52) Activity and safety of the novel bispecific antibody zanidatamab for previously treated HER2-amplified biliary tract cancer (BTC) (14:11) Key findings with tucatinib/trastuzumab for previously treated HER2-positive BTC (21:56) Antitumor activity observed with T-DXd in patients with BTC with HER2 mutations in the Phase II DESTINY-PanTumor02 trial (23:39) CME information and select publications

Featuring an interview with Dr Kanwal Raghav, including the following topics: Activity and tolerability of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing colorectal cancer (CRC) (0:00) Case: A woman in her mid 50s with multiregimen-refractory metastatic CRC receives T-DXd on a clinical trial (11:19) Case: A woman in her early 60s with advanced intrahepatic cholangiocarcinoma receives zanidatamab on a clinical trial (18:11) Molecular pathways and mechanisms of HER2 in cancer; clinical implications and future directions for gastrointestinal cancers (20:33) Evolving paradigm surrounding HER2 and other oncogene-addicted targets (29:32) CME information and select publications

Featuring perspectives from Dr Bita Fakhri, including the following topics: Overview of select presentations from ASH 2023; recent FDA approval of lisocabtagene maraleucel (0:00) 6-year follow-up from the Phase III CLL14 trial of first-line venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for chronic lymphocytic leukemia (CLL) (7:36) Updates from ASH 2023 from the Phase III FLAIR study of minimal residual disease (MRD)-guided ibrutinib in combination with venetoclax for previously untreated CLL (13:28) 57-month follow-up from the Phase III GLOW trial of fixed-duration ibrutinib/venetoclax for previously untreated CLL (22:28) Current clinical role of MRD testing for CLL (28:11) Key findings from 5-year follow-up of the Phase II CAPTIVATE study for patents with CLL/small lymphocytic leukemia (SLL) with relapse after first-line fixed-duration ibrutinib/venetoclax (36:43) 6-year update from the Phase III ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for treatment-naïve CLL (41:57) Updates from ASH 2023 for the management of relapsed/refractory CLL (54:30) Recent updates for the management of double-refractory CLL (58:05) Novel therapies under investigation for patients with CLL/SLL (1:10:57) Key findings guiding the clinical management of Richter's transformation (1:13:44) Case: A man in his early 80s with IGHV-unmutated del(17p) CLL experiences disease progression 3 years after completing second-line venetoclax-based therapy (1:22:17) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer | Faculty Presentation 2: Other Considerations in the Management of CRC — Arvind Dasari, MD, MS CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer | Faculty Presentation 1: Targeted Treatment Approaches for Colorectal Cancer (CRC) — Thierry André, MD CME information and select publications

Featuring perspectives from Prof Thierry André and Dr Arvind Dasari, including the following topics: Introduction: Year in Review on the Ground (0:00) Treatment of HER2-Positive Colorectal Cancer (CRC) (7:50) Immune Checkpoint Inhibitors for Microsatellite Instability-High CRC (24:12) Other Key Issues (45:30) Questions and Cases from the Community (52:30) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder Cancer | Faculty Presentation 2: Metastatic Disease — Thomas Powles, MBBS, MRCP, MD CME information and select publications

Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder Cancer | Faculty Presentation 1: Nonmetastatic Urothelial Bladder Cancer (UBC) — Shilpa Gupta, MD CME information and select publications